Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Diabetic Kidney Disease
NCT01683409Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2012
- Primary completion
- Sep 2014
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 4
01
Overview
A Phase 2 trial of baricitinib in diabetic kidney disease (DKD), sponsored by Eli Lilly and Company. Started Aug 2012; status: completed.
02
Drugs
baricitinib
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT01683409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01683409.